Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar
This study has been completed.
Sponsor:
Sanofi-Aventis
Information provided by:
Sanofi-Aventis
ClinicalTrials.gov Identifier:
NCT00594347
First received: December 19, 2007
Last updated: February 22, 2010
Last verified: February 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The present study intends to investigate the use as a booster of a dose of sanofi pasteur's Pneumo 23 vaccine in the second year of life following 3-dose priming with Wyeth's Prevnar vaccine. The researchers will use a cohort of subjects who have received 3 doses of Prevnar® at 2, 4, 6 months of age in the context of the clinical study A3L12 on Hexavalent combined vaccine (DTaP-IPV-HB-PRP~T)
Condition | Intervention | Phase |
---|---|---|
Streptococcus Pneumoniae |
Biological: Pneumo 23 Biological: Prevnar |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
Official Title: | Immunogenicity and Safety of a Booster Dose of Polysaccharide Pneumococcal Vaccine (Pneumo 23®) in 12 to 18 Months-Old Children Primed With Three Doses of Pneumococcal Conjugate Vaccine (Prevnar®) in Thailand. |
Resource links provided by NLM:
Further study details as provided by Sanofi-Aventis:
Primary Outcome Measures:
- To provide information concerning the safety after booster administration of 23-valent polysaccharidic pneumococcal vaccine [ Time Frame: 30 days post-vaccination ] [ Designated as safety issue: No ]
Enrollment: | 339 |
Study Start Date: | November 2007 |
Study Completion Date: | April 2009 |
Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: Group A
Pneumo 23
|
Biological: Pneumo 23
Vaccine (Pneumo 23)
|
Active Comparator: Group B
Prevnar
|
Biological: Prevnar
Vaccine (Prevnar)
|
Eligibility
Ages Eligible for Study: | 12 Months to 18 Months |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Aged 12 to 18 months on the day of inclusion
- Informed consent form signed by the parent/legally acceptable representative and by an independent witness if requested by local Ethics Committee regulation or/and if the parent/legally acceptable representative is illiterate
- Child having completed the three-dose primary vaccination of Prevnar® in the hexavalent combined vaccine study (study A3L12).
- Subjects and parent/guardian able to attend all scheduled visits and comply with all study procedures
Exclusion Criteria:
- Participation in another clinical study investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the study vaccination
- Planned participation in another clinical study during the present study period
- Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy
- Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the study vaccine or to a vaccine containing any of the same substances
- Chronic illness at a stage that could interfere with study conduct or completion, in the opinion of the investigator
- Receipt of blood or blood-derived products since birth that might interfere with the assessment of immune response
- Receipt of any vaccine in the 4 weeks preceding the study vaccination
- Planned receipt of any vaccine in the 4 weeks preceding or following study vaccination
- History of seizures Known personal Human Immunodeficiency Virus (HIV), Hepatitis B (HB) antigen or Hepatitis C seropositivity
- History of pneumococcal infection (confirmed either clinically, serologically or microbiologically)
- Previous booster vaccination against the pneumococcal disease with either the study vaccine(s) or another vaccine
- Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating IM vaccination
- Febrile illness (temperature ≥ 38°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment.
Contacts and Locations
More Information
Additional Information:
No publications provided
Keywords provided by Sanofi-Aventis:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 17, 2012
Additional Information:
Related Info 
Related Info 
No publications provided
Responsible Party: | sanofi pasteur, sanofi aventis |
ClinicalTrials.gov Identifier: | NCT00594347 History of Changes |
Other Study ID Numbers: | PNA19 |
Study First Received: | December 19, 2007 |
Last Updated: | February 22, 2010 |
Health Authority: | Thailand: Ministry of Public Health |
Keywords provided by Sanofi-Aventis:
Streptococcus pneumoniae |
Additional relevant MeSH terms:
Pneumonia Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections |
ClinicalTrials.gov processed this record on October 17, 2012